stay updated with our newsletter

Could the Endocannabinoid System Offer a New Treatment Target for Obsessive Compulsive Disorder?

THC or CBD Content

The disabling condition of obsessive-compulsive disorder (OCD) affects about 2–3% of people worldwide. Evidence suggests that abnormalities in cortico-striatal-thalamic-cortical circuitry and specific gene variants contribute to the pathogenesis of the disorder. This latest study, published in Cannabis and Cannabinoid Research, suggests that the endocannabinoid system (ECS) plays a role in OCD symptomsRead


Weekly round-up, access to thought leaders, and articles to help you improve health outcomes and the success of your practice.